OncoMatch

OncoMatch/Clinical Trials/NCT04316364

A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC

Is NCT04316364 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including SHR-1316、Paclitaxel (Albumin Bound)、Carboplatin and SHR-1316、Chemotherapeutic for non-small-cell lung cancer.

Phase 3RecruitingJiangsu HengRui Medicine Co., Ltd.NCT04316364Data as of Jun 2026Location: China

Treatment: SHR-1316、Paclitaxel (Albumin Bound)、Carboplatin · SHR-1316、ChemotherapeuticThis trial is designed to evaluate the efficacy, safety and immunogenicity of neoadjuvant treatment with monoclonal antibody SHR-1316 or placebo in combination with platinum doublet chemotherapy in participants with resectable Stage II, IIIA, or selected IIIB non-small cell lung cancer (NSCLC) followed by adjuvant SHR-1316 or placebo and monitoring.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Chemotherapy

SHR-1316、Paclitaxel (Albumin Bound)、Carboplatin

Other

SHR-1316、Chemotherapeutic

Cancer type

Non-Small Cell Lung Carcinoma

Biomarker criteria

Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)

Disease stage

Required: Stage II, IIIA, SELECTED IIIB

Performance status

ECOG 0–1(Restricted strenuous activity)

Demographics

Ages ≤ 70

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: systematic anti-cancer therapy

Any previous systematic anti-cancer therapy for lung cancer

Lab requirements

Blood counts

adequate organ function

Kidney function

adequate organ function

Liver function

adequate organ function

Adequate organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT04316364 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

Does this trial require CD274?

Yes, CD274 any tested is a required biomarker for enrollment.

What disease stage is eligible?

Stage II or IIIA or SELECTED IIIB is required.

Is there an age limit?

Yes. Patients must be 70 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify